Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (TANGOKIDS)

An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections

A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections

Study Overview

• Status: Recruiting
• Conditions: Bacterial Infections
• Intervention / Treatment: Drug: Vabomere

Detailed Description

In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of "last defense" for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many hospitals worldwide now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.

Rempex developed meropenem-vaborbactam administered as a fixed combination by IV infusion, to treat serious Gram-negative infections, such as cUTIs, including those infections caused by bacteria resistant to currently available carbapenems.

This study is an open label, dose-finding, pharmacokinetics, safety, and tolerability study of a single dose infusion of meropenem-vaborbactam in pediatric subjects from birth to less than 18 years of age with suspected or confirmed bacterial infection receiving antibiotic therapy or subjects receiving peri-operative prophylactic use of antibiotics.

• Study Type: Interventional
• Enrollment (Estimated): 67
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Richard J Lazauskas, DC; Phone Number: 1-844-633-6568; Email: rlazauskas@melinta.com
• Study Contact Backup: Name: William Waverczak, MS; Phone Number: 1-908-617-1308; Email: wwaverczak@melinta.com

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72202
      • Completed
      • Arkansas Children's Hospital
  • California
    • Los Angeles, California, United States, 90095
      • Recruiting
      • Ronald Reagan UCLA Medical Center
      • Principal Investigator: Jaime Deville, MD
      • Contact: Margarida Lei; Email: ylei@mednet.ucla.edu
    • Orange, California, United States, 92868
      • Recruiting
      • Children's Hospital of Orange County
      • Principal Investigator: Antonio Arrieta, MD
      • Contact: Claudia Enriquez, CCRC; Email: cenriquez@choc.org
    • San Diego, California, United States, 92123
      • Recruiting
      • Rady Children's Hospital San Diego
      • Principal Investigator: John Bradley, MD
      • Contact: Mary Jordan; Email: mjordan@rchsd.org
    • Torrance, California, United States, 90502
      • Withdrawn
      • Los Angeles Biomedical Research Institute
  • Illinois
    • Chicago, Illinois, United States, 60614
      • Recruiting
      • Ann & Robert H. Lurie Children's Hospital of Chicago
      • Contact: Laura Fearn; Email: LFearn@luriechildrens.org
      • Principal Investigator: William Muller, M.D.
      • Contact: Harrison Lee; Email: halee@luriechildrens.org
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Recruiting
      • University of Nebraska Medical Center
      • Principal Investigator: Kari Simonsen, MD
      • Contact: Laura Fischer; Email: laura.fischer@unmc.edu
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Completed
      • Rutger's University
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Completed
      • Rainbow Babies and Childrens Hospital
    • Toledo, Ohio, United States, 43606
      • Completed
      • Toledo Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. A signed and dated written informed consent from the parent or legal representative and a subject assent (according to local IRB requirements);
2. Male or female from birth to < 18 years of age;
3. Are hospitalized, in stable condition, and receiving systemic antibiotics for a known or suspected bacterial infection; or subjects receiving peri-operative prophylactic use of antibiotics;
4. The subject will be observed in the hospital for at least 6 hours after the study drug is administered;
5. If female and has reached menarche, or has reached Tanner Stage 3 breast development (even if not having reached menarche), the subject is practicing appropriate birth control or is sexually abstinent;
6. Sufficient intravascular access (peripheral or central) to receive study drug.

Subjects will be excluded from the study if any of the following exclusion criteria apply prior to randomization:

1. Signs of severe sepsis including:

   1. Shock or profound hypotension that is not responsive to fluid challenge;
   2. Hypothermia (core temperature < 35.6 ºC or 96.1 ºF);
   3. Disseminated intravascular coagulation as evidenced by prothrombin time or partial thromboplastin time ≥ 2X the ULN or platelets < 50% of the lower limit of normal;
2. Any surgical or medical condition which, in the opinion of the investigator, would put the subject at increased risk or is likely to interfere with study procedures or PK of the study drug;
3. Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant) during the entire study period;
4. Female adolescent subjects who are pregnant or breastfeeding or have a positive serum β-hCG pregnancy test at screening and at pre-dose Day 1;
5. Males who are unwilling to practice abstinence or use an acceptable method of broth control during the entire study period (i.e. condom with spermicide);

6. Renal function at screening as estimated by creatinine clearance < 50 mL/min /1.73 m^2 as calculated using the updated Schwartz bedside formula: eGFR = k x (height in cm) ÷ serum creatinine

   • k = 0.33 in pre-term infants.
   • k = 0.45 in term infants to 1 year of age.
   • k = 0.55 in children and adolescent girls.
   • k = 0.70 in adolescent boys.
7. Treatment within 30 days prior to enrollment with valproic acid;
8. Treatment within 30 days prior to enrollment with probenecid;
9. Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis or hepatic encephalopathy;
10. Neutropenia with absolute neutrophil count (ANC) < 500 cells/mm3;
11. Aspartate aminotransferase or alanine aminotransferase ≥ 3X ULN or total bilirubin ≥ 1.5X ULN;
12. Receipt of any investigational medication or investigational device within 30 days prior to enrollment;
13. Prior exposure to vaborbactam or Vabomere;
14. Use of meropenem within 48 hours of administration of study drug or 12 hours after study drug administration;
15. Known significant hypersensitivity to any beta-lactam antibiotic;
16. Unable or unwilling in the judgment of the Investigator, to comply with the protocol;
17. Subject is a child of an employee of the Investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member of the employee or the Investigator;
18. Body Mass Index (BMI) outside the range (below the 5th percentile or above the 95th percentile) for height, age and weight except for children < 2 years of age.)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Single dose IV meropenem-vaborbactam; Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours; Cohort 1 (n=8): 12 to < 18 years of age (40 mg/kg); Cohort 2 (n=8): 6 to < 12 years of age (40 mg/kg); Cohort 2b (n=4): 6 to < 12 years of age (60 mg/kg); Cohort 3 (n=8): 2 to < 6 years of age (60 mg/kg); Cohort 4 (n=8): 3 months to < 2 years of age (60 mg/kg); Cohort 5 (n=24): Birth to < 3 months of age (dose TBD)Group A: Gestational Age (GA) < 32 weeks, Postnatal Age (PNA) < 2 weeks (n=6)Group B: GA < 32 weeks, PNA > 2 weeks (n=6)Group C: GA > 32 weeks, PNA < 2 weeks (n=6)Group D: GA > 32 weeks, PNA > 2 weeks (n=6); Cohort 6 (n=7): 2 to < 12 years of age and ≤ 35 kg of weight (80 mg/kg)

Drug: Vabomere; Vabomere (meropenem-vaborbactam) for IV injection; Other Names: Combination meropenem and vaborbactam; carbapenem and beta-lactamase inhibitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics: AUC0-∞	AUC from time zero to infinity	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: Cmax	maximum measured plasma concentration	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: time to maximum plasma concentration (Tmax)	time to Cmax	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: drug clearance (CL)	total body clearance	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: t1/2	elimination half- life	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: Cmin	minimum plasma concentration	From pre-dose until 6 hours after the start of the infusion
Pharmacokinetics: Vss	Volume of distribution	From pre-dose until 6 hours after the start of the infusion
Safety and tolerability: AEs/SAEs	a composite measure of the number and types of AEs/SAEs encountered and relationship to time of dosing	From assent / consent until day 7 safety follow up call
Safety and tolerability: clinical safety laboratory results	A composite measure of multiple laboratory results assessing the clinical significance of any changes from baseline	From assent / consent until day 7 safety follow up call
Safety and tolerability: vital signs	A composite of multiple vital sign measurements, assessing the clinical significance of any changes from baseline	From assent / consent until day 7 safety follow up call
Safety and tolerability: ECGs	A composite of multiple ECG measurements, assessing the clinical significance of any changes from baseline	From assent / consent until day 7 safety follow up call

Collaborators and Investigators

• Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
• Collaborators: Department of Health and Human Services
• Investigators: Study Director: Study Director, Melinta Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2016
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: February 17, 2016
• First Submitted That Met QC Criteria: February 17, 2016
• First Posted (Estimated): February 22, 2016

Study Record Updates

• Last Update Posted (Actual): March 4, 2024
• Last Update Submitted That Met QC Criteria: March 1, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Bacterial Infections and Mycoses; Infections; Communicable Diseases; Bacterial Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Bacterial Agents; Meropenem; Vaborbactam; beta-Lactamase Inhibitors
• Other Study ID Numbers: Rempex 507; 2016-000656-99 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No